Wednesday, February 28, 2024

Lung Cancer | Screening | Liquid Biopsy, 02/28/2024

National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
Targeted Drug Expands Treatment Options for Lung Cancers with ROS1 Fusions
stylized lungs with a tumor   The results of the clinical trial that led to the Food and Drug Administration's (FDA) 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions have been published. The drug shrank tumors in 80% of people receiving it as first-line treatment.

Read More
Research Network to Evaluate Emerging Cancer Screening Technologies
man sits on a hospital bed while a health care provider rubs the crook of his elbow with alcohol   NCI has launched a clinical trials network to study emerging technologies for cancer screening. In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to inform the design of a larger trial of multi-cancer detection tests.

Read More
Priming Agents May Improve Liquid Biopsies
Drawing shows 2 test tubes, before priming agent and after priming agent. The after test tubs has more circulating tumor DNA.   Using two different techniques, researchers showed they could briefly boost circulating tumor DNA (ctDNA) levels in the blood of mice with tumors. With more ctDNA in collected blood draws, a liquid biopsy could better detect cancer, the research team found.

Read More
A Simple Tool Is Saving Lives of Children with Cancer in Latin America

A system for catching treatment-related complications in children with cancer has proven to be highly effective in many Latin American hospitals. An NCI-funded study aims to help these early warning systems last.

Read More

Lymphedema

Lymphedema, the buildup of lymph fluid in tissues causing swelling, affects function and quality of life. Learn about ways to prevent and treat it with exercise, compression, laser and drug therapy, surgery, massage, and more on this expert-reviewed page.

Read More

New Approval for Lung Cancer

FDA approval for osimertinib (Tagrisso) has been expanded. It is now approved to be used with chemotherapy as the first treatment for non-small cell lung cancer that has an abnormal EGFR gene and has spread.

Read More

Childhood Brain Tumors

Our pages on DIPG (diffuse intrinsic pontine glioma), childhood ependymoma, and childhood glioma (including astrocytoma) have a new look. The pages cover causes and risk factors, symptoms, screening, diagnosis, prognosis, stages, and treatment.

 
Contact Us
cancer information specialist   Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. This page tells you how to reach us by phone, chat, or email.

 

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892 GovDelivery logo

No comments:

Post a Comment

The Future is NOW: The Top 3 AI Stocks for 2025

If you are not able to see this mail, click here If you wish to unsubscribe from our newsletter, click here   Fellow Trader...